Natera, Inc. Announces Launch of Vistara Single-Gene Mutation NIPT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Natera (NTRA) PT Raised to $16 at Canaccord Genuity Following 1Q
May 10, 2017 8:45 AM EDTCanaccord Genuity raised its price target on Natera (NASDAQ: NTRA) to $16.00 (from $14.00) while maintaining a Buy rating. NTRA reported 1Q revenues of $46.9M beating the Street's $42.8 estimate.
NTRA reiterated 2017 revenue guidance of $210-230M, compared to the Street's $218.6M. Analyst Mark... More
